[Pulmonary fibrosis induced by amiodarone--a pitfall of antiarrhytmic treatment].

Cardiac arrhythmia are one of the major causes of cardiovascular and general morbi-mortality. This is the reason for a very quick and well-guided approach. One of the most used drug for this purpose is amiodarone, due to its high therapeutic potency and despite its risk for adverse effects. The most wellknown adverse effect seems to be the thyroid toxicity but, in reality, the most common ones involve the gastrointestinal and respiratory tract, with lung toxicity as a leader (incidence 6-7%). The two clinical cases which make the central point of this work are clear examples for being interested about amiodarone presence when a pulmonary fibrosis is present.